利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.045 秒)

    METHODS AND COMPOSITIONS FOR REDUCING THE RISK ASSOCIATED WITH THE ADMINISTRATION OF OPIOID ANALGESICS IN PATIENTS DIAGNOSED OR UNDIAGNOSED RESPIRATORY ILLNESS
    1.
    发明申请
    METHODS AND COMPOSITIONS FOR REDUCING THE RISK ASSOCIATED WITH THE ADMINISTRATION OF OPIOID ANALGESICS IN PATIENTS DIAGNOSED OR UNDIAGNOSED RESPIRATORY ILLNESS 审中-公开
    方法和组合物，用于降低与诊断或不良反应无效的患者中的阿片类药物治疗相关的风险

    公开(公告)号：US20120316189A1

    公开(公告)日：2012-12-13

    申请号：US13444073

    申请日：2012-04-11

    申请人： Gary W. Pace ,  Maree T. Smith

    发明人： Gary W. Pace ,  Maree T. Smith

    IPC分类号： A61K31/485 ,  A61P25/04

    CPC分类号： A61K45/06 ,  A61K31/445 ,  A61K31/485 ,  A61K2300/00

    摘要： The present invention relates to methods for reducing the risk associated with the administration of opioid analgesics in patient diagnosed or undiagnosed with respiratory illness by administering an analgesic composition comprising a sub-analgesic dosage of a p-opioid agonist selected from the group consisting a morphine, fentanyl, sufentanil, alfentanil, oxymorphone and hydromorphone, or a pharmaceutically acceptable salt thereof, and a sub-analgesic dosage of oxycodone which is a κ2-opioid agonist or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明涉及通过施用镇痛组合物来降低与诊断或未诊断为呼吸系统疾病的患者中阿片样镇痛药相关的风险的方法，所述止痛组合物包含选自以下组中的β-阿片样物质激动剂的亚类镇痛剂：吗啡， 芬太尼，舒芬太尼，阿芬太尼，羟吗啡酮和氢吗啡酮，或其药学上可接受的盐，以及作为阿片样物质激动剂或其药学上可接受的盐的羟考酮的次镇痛剂量。

    Spray drying process and compositions of fenofibrate
    6.
    发明授权
    Spray drying process and compositions of fenofibrate 有权
    喷雾干燥工艺和非诺贝特组合物

    公开(公告)号：US06696084B2

    公开(公告)日：2004-02-24

    申请号：US09838593

    申请日：2001-04-20

    申请人： Gary W. Pace ,  Awadesh K. Mishra ,  Robert A. Snow ,  Indu Parikh ,  Pol-Henri W. Guivarc'h

    发明人： Gary W. Pace ,  Awadesh K. Mishra ,  Robert A. Snow ,  Indu Parikh ,  Pol-Henri W. Guivarc'h

    IPC分类号： A61K914

    CPC分类号： A61K31/66 ,  A61K9/145 ,  A61K9/1623 ,  A61K31/216 ,  A61K31/22 ,  A61K31/365 ,  A61K31/40 ,  A61K31/405 ,  A61K31/44 ,  A61K31/505 ,  A61K45/06 ,  A61K31/215 ,  A61K2300/00

    摘要： The present invention relates to a novel spray drying process for the preparation of pharmaceutical compositions containing small particles of phospholipid-stabilized fenofibrate. This invention also relates to spray dried powdered compositions prepared according to this process, and to dosage forms of fenofibrate (capsules, tablets, powders, granules, and dispersions) prepared from these powdered compositions. The powdered compositions and dosage forms are useful in the treatment of dyslipidemia and dyslipoproteinemia and have the advantage that they provide reduced in vivo variability in the bioavailability of fenofibrate active species among fed and fasted patients when administered orally.

    摘要翻译： 本发明涉及一种用于制备含有磷脂稳定的非诺贝特的小颗粒的药物组合物的新型喷雾干燥方法。 本发明还涉及根据该方法制备的喷雾干燥的粉末组合物，以及由这些粉末状组合物制备的非诺贝特（胶囊，片剂，粉末，颗粒剂和分散体）的剂型。 粉末组合物和剂型可用于治疗血脂异常和血脂异常，并且具有这样的优点：当口服给药时，它们在进食和禁食患者中提供非诺贝特活性物质的生物利用度的体内变异性降低。

    Water-insoluble drug particle process
    7.
    发明授权
    Water-insoluble drug particle process 有权
    水不溶性药物颗粒过程

    公开(公告)号：US06682761B2

    公开(公告)日：2004-01-27

    申请号：US09838540

    申请日：2001-04-20

    申请人： Gary W. Pace ,  Awadesh K. Mishra

    发明人： Gary W. Pace ,  Awadesh K. Mishra

    IPC分类号： A61K914

    CPC分类号： A61K9/1688 ,  A61K9/145

    摘要： This invention relates to process for the preparation of small particles containing a poorly water soluble drug comprising (a) mixing at high shear an admixture of a poorly water soluble drug and one or more than one surface active substance in an aqueous carrier in the absence of an organic solvent within a first temperature range at or above the melting point of the poorly water soluble drug to form a heated suspension containing the drug, then (b) homogenizing said heated suspension in a first pressure range and within said first temperature range to form a heated homogenate containing the drug, then (c) cooling said heated homogenate to a second temperature range below the melting temperature of the poorly water soluble drug to form a transiently stable cooled homogenate containing the drug, then (d) applying a particle stabilizing energetic process to said cooled homogenate within a second temperature range below the melting point of the drug and in a second pressure range to form a cooled dispersion of stabilized small particles containing the drug, and then (e) optionally drying the cooled dispersion to form dried small particles containing the poorly water soluble drug.

    摘要翻译： 本发明涉及制备含水难溶性药物的小颗粒的方法，其包括（a）在高剪切下混合水不溶性药物与一种或多于一种表面活性物质在水性载体中的混合物， 在低水溶性药物的熔点以上的第一温度范围内的有机溶剂，形成含有药物的加热悬浮液，然后（b）在所述第一压力范围内并在所述第一温度范围内使所述加热的悬浮液均化，形成 含有药物的加热匀浆，然后（c）将所述加热的匀浆冷却至低于难溶性水溶性药物的熔融温度的第二温度范围，以形成含有药物的瞬时稳定的冷却匀浆，然后（d） 在低于药物熔点的第二温度范围内和在形成的第二压力范围内对所述冷却的匀浆进行处理 含有药物的稳定的小颗粒的冷却分散体，然后（e）任选地干燥冷却的分散体以形成干燥的含水难溶性药物的小颗粒。

    Milled particles
    8.
    发明授权
    Milled particles 有权

    公开(公告)号：US06634576B2

    公开(公告)日：2003-10-21

    申请号：US09940864

    申请日：2001-08-29

    申请人： Frank Verhoff ,  Gary W. Pace ,  Robert A. Snow ,  Fay Millar

    发明人： Frank Verhoff ,  Gary W. Pace ,  Robert A. Snow ,  Fay Millar

    IPC分类号： B02C1214

    CPC分类号： A61K9/14

    摘要： A process for milling a solid substrate in the milling chamber of a dispersion or media mill in the presence of a two or more compositions of milling media bodies is disclosed wherein all milling media bodies contribute to the grinding of the solid substrate and wherein at least one composition of media bodies provides fragments of milling media bodies that are retained with the milled solid substrate particles in the form of a synergetic commixture produced in the milling process. More specifically, a process is disclosed for preparing a synergetic commixture comprising small particles of a solid substrate and small particulates of a first material of a desired size comprising the steps of (a) providing to the milling chamber of a media mill a contents comprising a pre-mix of a solid substrate, a fluid carrier, a plurality of milling bodies of a first material having a fracture toughness Kc1, and a plurality of milling bodies of a second material having a fracture toughness Kc2; (b) operating the media mill to grind the solid substrate and degrade at least a portion of the milling bodies of first material to produce a dispersion in the fluid carrier comprising a synergetic commixture of small particulates of the first material and small particles of the solid substrate having a desired size equal to or less than a size Sp; (c) separating the dispersion from any milling bodies and solid substrate particles having a size larger than Sp; and (d) optionally removing the fluid carrier from the dispersion to form a synergetic commixture free of fluid and comprising the particles and the small particulates, wherein KC2 is greater than KC1.

    Composition and method of preparing microparticles of water-insoluble substances
    9.
    发明授权
    Composition and method of preparing microparticles of water-insoluble substances 有权
    制备水不溶性物质微粒的组成及方法

    公开(公告)号：US06337092B1

    公开(公告)日：2002-01-08

    申请号：US09650862

    申请日：2000-08-29

    申请人： Sheema Khan ,  Gary W. Pace

    发明人： Sheema Khan ,  Gary W. Pace

    IPC分类号： A61K914

    CPC分类号： A61K9/145 ,  A61K9/146 ,  Y10S977/906

    摘要： Pharmaceutical compositions comprising electrostatic and steric-stabilized sub-micron and micron-size stable microparticles of water-insoluble or poorly soluble drugs or other industrially useful insoluble compounds having diameters of about 0.05 to about 10 microns are described. The particles have phospholipid coated surfaces and are stabilized with a combination of charged surface modifier and block copolymer. The diameter of the particles is greater than about 50% but less than 100% of the diameter of particles comprising the poorly soluble drug and the phospholipid coated surfaces prepared by otherwise identical means in the absence of the combination of charged surface modifier and block copolymer. The charged surface modifier provides electrostatic stabilization and the block copolymer provides steric stabilization that minimize particle size growth caused by Ostwald ripening and particle aggregation and provides for small particle formation. The compositions of particles can be in the form of suspensions or powders that can be converted to other dosage forms.

    摘要翻译： 描述包含具有约0.05至约10微米直径的静电和空间稳定的亚微米和微米尺寸稳定的水不溶性或难溶性药物微粒或其他工业上有用的不溶性化合物的药物组合物。 颗粒具有磷脂涂覆表面，并且通过带电表面改性剂和嵌段共聚物的组合来稳定。 颗粒的直径大于包含难溶性药物的颗粒的直径的大约50％但小于100％，而在不存在带电表面改性剂和嵌段共聚物的组合的情况下通过其它方式相同的方法制备的磷脂涂覆的表面。 带电表面改性剂提供静电稳定性，并且嵌段共聚物提供空间稳定化，使由Ostwald熟化和颗粒聚集引起的粒度增长最小化并提供小颗粒形成。 颗粒的组成可以是可以转化成其他剂型的悬浮液或粉末的形式。